ACIU - AC Immune SA
| Previous Close | 9.65 |
| Open | 9.64 |
| Bid | 7.60 x 900 |
| Ask | 15.90 x 900 |
| Day's Range | 9.40 - 9.84 |
| 52 Week Range | 7.16 - 17.40 |
| Volume | 34,918 |
| Avg. Volume | 129,855 |
| Market Cap | 658.134M |
| Beta (3Y Monthly) | 1.11 |
| PE Ratio (TTM) | N/A |
| EPS (TTM) | -0.48 |
| Earnings Date | Nov 12, 2018 - Nov 16, 2018 |
| Forward Dividend & Yield | N/A (N/A) |
| Ex-Dividend Date | N/A |
| 1y Target Est | 21.95 |
- GlobeNewswire•2 days ago
AC Immune Awarded Third Follow-up Grant from The Michael J. Fox Foundation for First-in-Human Study of a Positron Emission Tomography (PET) Tracer for Parkinson's Disease
AC Immune SA (ACIU), a Swiss-based, clinical-stage biopharmaceutical company with a broad pipeline focused on neurodegenerative diseases, today announced it has been awarded a follow-up grant from The Michael J. Fox Foundation for Parkinson's Research (MJFF). In 2015 AC°Immune received a research grant from the MJFF to support the development of a Parkinson's-specific diagnostic agent. Following a grant extension in 2017, the new grant is an acknowledgement of the progress AC Immune has made in this program.
- Zacks•4 days ago
AC Immune (ACIU) Reports Q3 Loss, Tops Revenue Estimates
AC Immune (ACIU) delivered earnings and revenue surprises of 30.77% and 36.73%, respectively, for the quarter ended September 2018. Do the numbers hold clues to what lies ahead for the stock?
- GlobeNewswire•4 days ago
AC Immune Reports Third Quarter 2018 Financial Results and Corporate Update
Announced important clinical milestones for ACI-24 vaccine in Alzheimer's disease and Down Syndrome Company record high, period end cash position of approximately CHF 200.
- GlobeNewswire•5 days ago
AC Immune to Present at the Jefferies 2018 London Healthcare Conference
Lausanne, Switzerland, November 12, 2018 - AC Immune SA (NASDAQ: ACIU), a Swiss-based, clinical-stage biopharmaceutical company with a broad pipeline focused on.
- GlobeNewswire•8 days ago
AC Immune Shares Insights from Key Opinion Leader Meeting on Abeta Oligomers in Alzheimer's Disease (AD) and Other Misfolded Proteins in AD and Neurodegenerative Diseases
Immunotherapies and small molecule anti-Tau therapeutics hold much promise in treating AD and neurodegenerative orphan indications. Lausanne, Switzerland, November 9, 2018 - AC Immune SA (ACIU), a Swiss-based, clinical-stage biopharmaceutical company with a broad pipeline focused on neurodegenerative diseases, shared top level insights from its Key Opinion Leader (KOL) luncheon meeting on Abeta oligomers and concomitant proteinopathies in AD and other neurodegenerative diseases, which took place on November 5, 2018, in New York City.
- Zacks•12 days ago
Earnings Preview: AC Immune (ACIU) Q3 Earnings Expected to Decline
AC Immune (ACIU) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
- GlobeNewswire•16 days ago
AC Immune to Present at 2018 Society for Neurosciences Meeting
Update on Therapeutic and Diagnostic Programs Targeting TDP-43 Lausanne, Switzerland, November 1, 2018 - AC Immune SA (NASDAQ: ACIU), a Swiss-based, clinical-stage.
- GlobeNewswire•16 days ago
AC Immune to Host Key Opinion Leader Meeting on Abeta Oligomers in Alzheimer's Disease (AD) and the Involvement of Other Misfolded Proteins in AD and Neurodegenerative Diseases
Key Opinion Leaders to discuss emerging concepts in the development of therapies for Alzheimer's Disease and other neurodegenerative diseasesMeeting scheduled for November 5,.
- GlobeNewswire•19 days ago
AC Immune Partner Life Molecular Imaging Presents New Clinical Study Results for Tau PET-Tracer 18F-PI-2620
AC Immune SA (ACIU), a Swiss-based, clinical-stage biopharmaceutical company focused on neurodegenerative diseases, today announced that its partner Life Molecular Imaging (LMI, formerly Piramal Imaging) has presented new clinical study results for 18F-PI-2620, a novel tau PET-tracer, allowing further extension of tau PET investigations with this compound in therapeutic clinical trials[1].
- GlobeNewswire•19 days ago
AC Immune SA: New Data Supporting Crenezumab as Potential Alzheimer's Therapy
Lausanne, Switzerland, October 29, 2018 AC Immune SA (ACIU), a Swiss-based, clinical-stage biopharmaceutical company focused on neurodegenerative diseases, today announced the presentation of in vitro data that underscores the clinical rationale for crenezumab, an anti-beta amyloid antibody, as a potential treatment for Alzheimer's disease (AD)[1]. Furthermore, the results of a study on PET eligibility supported the use of either amyloid PET or the Elecsys® ß-Amyloid (1-42) CSF immunoassay as eligibility criteria in the CREAD Phase 3 studies of crenezumab in patients with prodromal-to mild AD[2].
- GlobeNewswire•23 days ago
AC Immune Selected to Present Progress on its Tau Morphomer Program in the Late Breaking News Session at CTAD Conference in Barcelona
AC Immune SA (ACIU), a Swiss-based, clinical-stage biopharmaceutical company with a broad pipeline focused on neurodegenerative diseases has been selected for an oral presentation in the late breaking session at the 11th annual Clinical Trials on Alzheimer's Disease (CTAD18) conference, taking place in Barcelona, Spain, from October 24th to 27th. The presentation with the title "Identification and characterization of small molecule clinical candidates targeting intracellular tau pathology" was selected for the late breaking communication session to be held at 3:45pm (CET) on Saturday, October 27th, and will be given by Dr. Sonia Poli, AC Immune's Head of Translational Science. In April 2018, AC Immune announced the selection of tau small molecule candidates for clinical development in Alzheimer's disease (see press release).
- GlobeNewswire•26 days ago
AC Immune Announces Dr. Andreas Muhs, Chief Scientific Officer, to Take Medical Leave of Absence
Lausanne, Switzerland, October 22, 2018 - AC Immune SA (NASDAQ: ACIU), a Swiss-based, clinical-stage biopharmaceutical company with a broad pipeline focused on neurodegenerative.
- GlobeNewswire•last month
Investor Expectations to Drive Momentum within Matthews International, AC Immune SA, Entercom Communications, Sunrun, Axcelis Technologies, and Advanced Disposal Services — Discovering Underlying Factors of Influence
NEW YORK, Oct. 17, 2018 -- In new independent research reports released early this morning, Market Source Research released its latest key findings for all current investors,.
- GlobeNewswire•3 months ago
Recent Analysis Shows STMicroelectronics N.V, Jagged Peak Energy, Inovalon, AC Immune SA, Repligen, and RealNetworks Market Influences — Renewed Outlook, Key Drivers of Growth
NEW YORK, Aug. 22, 2018-- In new independent research reports released early this morning, Fundamental Markets released its latest key findings for all current investors, traders, and shareholders of STMicroelectronics ...
- GlobeNewswire•3 months ago
AC Immune Announces Important Clinical Milestones for ACI-24 Vaccine in Alzheimer's Disease and Down Syndrome
AC Immune SA (ACIU), a Swiss-based, clinical-stage biopharmaceutical company with a broad pipeline focused on neurodegenerative diseases, today announced two clinical milestone events related to ACI-24, its anti-Abeta vaccine against Alzheimer's disease and Abeta-related cognitive decline in Down Syndrome. Prof. Andrea Pfeifer, CEO of AC Immune, said: "We are delighted with the progress of ACI-24, the anti-Abeta vaccine, derived from our proprietary SupraAntigenTM platform. In addition to the development in Alzheimer's Disease, it is currently the only clinical-stage vaccine targeting the associated Abeta-induced cognitive decline in people with Down Syndrome.
- Zacks•3 months ago
AC Immune (ACIU) Reports Q2 Loss, Tops Revenue Estimates
AC Immune (ACIU) delivered earnings and revenue surprises of 13.04% and 5.78%, respectively, for the quarter ended June 2018. Do the numbers hold clues to what lies ahead for the stock?
- Motley Fool•4 months ago
Here's Why AC Immune SA Rose as Much as 21.6% Today
The early-stage biopharma announced more details about a share offering to raise much-needed capital.
